This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Investigators from multiple institutions in the United Kingdom conducted a randomized controlled trial to assess the efficacy of omalizumab, an anti-immunoglobulin (Ig)E medication, for treatment of severe eczema in children. Study participants were patients 4–19 years old with severe eczema, defined as an objective Scoring Atopic Dermatitis (SCORAD) index of >40, that was unresponsive to topical or systemic therapy. SCORAD is a validated instrument to assess eczema and has possible scores ranging from 0 to 103; both objective and subjective components are included. At enrollment, additional baseline measurements included total IgE level, Eczema Area and Severity Index (EASI, a validated measure of the physical signs of eczema) score, and Children’s Dermatology Life Quality Index/Dermatology Life Quality Index (CDLQI/DLQI) score. Study patients were randomized …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.